Boston Scientific Announces Australia and New Zealand Approval for its LATITUDE(R) Patient Management System

NATICK, Massachusetts, November 18, 2010 - Boston Scientific Corporation (NYSE: BSX) today announced
Australian and New Zealand regulatory approval and launch of its LATITUDE(R)
Patient Management system. The LATITUDE system enables physicians to remotely
monitor patients with implantable cardiac devices, gathering information on
both the device and a patient's heart health status. The system can also
detect clinical events between scheduled physician visits and send relevant
data directly to a patient's physician.

"Boston Scientific has enrolled more than 170,000 patients on
the LATITUDE system since its introduction in the U.S. in 2006, making it the
most rapidly adopted remote cardiac device monitoring system in the
industry," said Hank Kucheman, Executive Vice President and President of
Boston Scientific Cardiology, Rhythm and Vascular Group. "We expect continued
success as we introduce the demonstrated benefits of our LATITUDE system to
patients and physicians in Australia and New Zealand. Remote monitoring
technology provides a significant opportunity to further impact patient
care."

LATITUDE is the only remote cardiac device monitoring system
to offer a wireless weight scale and blood pressure monitor, both of which
are recommended by the American College of Cardiology and American Heart
Association physician societies for the management of heart failure patients.

The Australian and New Zealand version of the LATITUDE system
is compatible with the Company's wireless COGNIS(R) cardiac resynchronization
therapy defibrillator (CRT-D) and TELIGEN(R) implantable cardioverter
defibrillator (ICD), the world's smallest and thinnest high-energy devices.

Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please visit:
www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934. Forward-looking statements may be
identified by words like "anticipate," "expect," "project," "believe,"
"plan," "estimate," "intend" and similar words. These forward-looking
statements are based on our beliefs, assumptions and estimates using
information available to us at the time and are not intended to be guarantees
of future events or performance. These forward-looking statements include,
among other things, statements regarding new product launches and launch
cadence, regulatory approvals, clinical trials, product performance and
competitive offerings. If our underlying assumptions turn out to be
incorrect, or if certain risks or uncertainties materialize, actual results
could vary materially from the expectations and projections expressed or
implied by our forward-looking statements. These factors, in some cases, have
affected and in the future (together with other factors) could affect our
ability to implement our business strategy and may cause actual results to
differ materially from those contemplated by the statements expressed in this
press release. As a result, readers are cautioned not to place undue reliance
on any of our forward-looking statements.

Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends; intellectual
property; litigation; financial market conditions; and, future business
decisions made by us and our competitors. All of these factors are difficult
or impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and
uncertainties that may affect our future operations, see Part I, Item 1A -
Risk Factors in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II, Item 1A -
Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file
hereafter. We disclaim any intention or obligation to publicly update or
revise any forward-looking statements to reflect any change in our
expectations or in events, conditions, or circumstances on which those
expectations may be based, or that may affect the likelihood that actual
results will differ from those contained in the forward-looking statements.
This cautionary statement is applicable to all forward-looking statements
contained in this document.

    CONTACT: Paul Donovan
    +1-508-650-8541 (office)
    +1-508-667-5165 (mobile)
    Media Relations
    Boston Scientific Corporation

    David Knutson
    +1-651-260-8288 (mobile)
    Media Relations
    Boston Scientific Corporation

    Larry Neumann
    +1-508-650-8696 (office)
    Investor Relations
    Boston Scientific Corporation

CONTACT: Paul Donovan, +1-508-650-8541 (office), +1-508-667-5165 (mobile), Media Relations, Boston Scientific Corporation; David Knutson, +1-651-260-8288 (mobile), Media Relations, Boston Scientific Corporation; Larry Neumann, +1-508-650-8696 (office), Investor Relations, Boston Scientific Corporation